|
May 03, 2022
|
PTC Therapeutics Provides a Corporate Update and Reports First Quarter Financial Results
- $149 million total revenue representing impressive 26% year-over-year growth – - Initiation of PIVOT-HD Phase 2 trial of PTC518 in Huntington's disease – - CHMP opinion on AADC gene therapy expected in May; ready to execute on potential launch – SOUTH PLAINFIELD, N.J.
|
|
|
Apr 29, 2022
|
PTC Therapeutics to Participate at Upcoming Investor Conferences
SOUTH PLAINFIELD, N.J. , April 29, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company overview at the following conferences: Bank of America Securities 2002 Healthcare Conference Tuesday, May 10 at 5:20 p.m.
|
|
|
Apr 19, 2022
|
PTC Therapeutics to Host Conference Call to Discuss First Quarter 2022 Financial Results
SOUTH PLAINFIELD, N.J. , April 19, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its first quarter 2022 financial results and provide an update on the company's business and outlook on Tuesday, May 3 , at
|
|
|
Apr 14, 2022
|
PTC Therapeutics Provides Update on EMA Regulatory Review Timeline For Its AADC Deficiency Gene Therapy Program
- CHMP Opinion Now Expected May 2022 - SOUTH PLAINFIELD, N.J. , April 14, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) announced today that it has completed the Scientific Advisory Group and Oral Explanation meetings for its gene therapy treatment for AADC deficiency (PTC-AADC) with
|
|
|
Apr 08, 2022
|
PTC Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
SOUTH PLAINFIELD, N.J. , April 8, 2022 /PRNewswire/ -- PTC Therapeutics , Inc. (NASDAQ: PTCT) today announced that on April 8, 2022 , the company approved non-statutory stock options to purchase an aggregate of 86,130 shares of its common stock and 33,125 restricted stock units ("RSUs"), each
|
|
|
Mar 30, 2022
|
PTC Therapeutics Announces Initiation of PIVOT-HD Phase 2 Clinical Trial to Evaluate PTC518 in Patients with Huntington's Disease
SOUTH PLAINFIELD, N.J. , March 30, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the initiation of the PIVOT-HD Phase 2 clinical trial evaluating PTC518 in people with Huntington's disease (HD). PIVOT-HD is a global trial starting in the United States .
|
|
|
Mar 11, 2022
|
PTC Therapeutics to Present New Data at the 2022 Muscular Dystrophy Association Clinical & Scientific Conference
SOUTH PLAINFIELD, N.J. , March 11, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present three posters outlining data for EMFLAZA™ (deflazacort) in Duchenne muscular dystrophy (DMD) at the Muscular Dystrophy Association (MDA) Clinical & Scientific
|
|
|
Feb 23, 2022
|
PTC Therapeutics to Participate at Upcoming Investor Conferences
SOUTH PLAINFIELD, N.J. , Feb. 23, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company update at the following conferences: Cowen Virtual 42nd Annual Health Care Conference Monday, March 7 at 1:30 p.m.
|
|
|
Feb 22, 2022
|
PTC Therapeutics Provides a Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results
- $539 million 2021 total revenue representing impressive 41% year-over-year growth - - Continued pipeline progress with five registration-directed clinical trials ongoing - - $700-750 million 2022 total revenue guidance reaffirmed - SOUTH PLAINFIELD, N.J. , Feb.
|
|
|
Feb 08, 2022
|
PTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Year-End 2021 Financial Results
SOUTH PLAINFIELD, N.J. , Feb. 8, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its fourth quarter and year-end 2021 financial results and provide an update on the company's business and outlook on Tuesday,
|
|
